Technology Bundle ID

Combination Therapy for Prostate and Breast Cancer

Lead Inventors
Jeffrey Schlom (NCI)
James Hodge (NCI)
Development Status
Pre-clinical (in vivo)

Endocrine deprivation therapy and other hormone therapy treatments are the standard of care for prostate cancer and breast cancer using FDA approved agents such as enzalutamide and abiraterone. However, some prostate cancer and breast cancer patients acquire a resistant to these existing therapies. There is an unmet need for novel, combination therapies to treat these cancer patients.

Researchers at the National Cancer Institute Laboratory of Tumor Immunology and Biology, developed a method of immunogenic modulation in androgen and endocrine deprivation therapy. They showed that immunogenic modulation by two approved drugs, enzalutamide and abiraterone, increases cytotoxic T lymphocyte (CTL) sensitivity in prostate tumor and breast cancer cells. The researchers observed a reduction in prostate cancer cell growth by treating cancer cells with a combination of androgen deprivation therapy and immunotherapy. The researchers also applied this method to reduce breast cancer cell growth using a combination of endocrine deprivation therapy and immunotherapy. These results are distinct from the known mechanism of action of androgen and endocrine deprivation therapeutics, and highlight a mechanism whereby hormone deprivation therapy can be used in combination with immunotherapy to enhance antitumor activity. 

The National Cancer Institute, Laboratory of Tumor Immunology and Biology, seeks parties to co-develop this combination of hormone therapy and immunotherapy for the treatment of prostate and breast cancer.

Commercial Applications

- Combination immunotherapy regimen for prostate and breast cancer treatment

Competitive Advantages

- Beneficial to prostate and breast cancer patients that have acquired resistance to the stand-alone androgen or endocrine deprivation therapy

Request More Info

Licensing Contact: